RxDoctor Payments Data

Aditya Bharadwaj, MD

Interventional Cardiology · Loma Linda, CANPI 1871729822

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $304,675 of the $380,374 with a category attached, or 80.1%. Abiomed accounts for 90.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $111,384 and has fallen 86.9% since, to $14,642 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$380,374in general payments, 2019–2025

Across 324 payments — averaging $1173.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$343K
  • Cardiovascular Systems Inc.$15K
  • Shockwave Medical, Inc$14K
  • Abbott$7K
  • Boston Scientific$673
  • Medtronic$320
  • plus $270 from 6 others
$10,612in research payments, 2019–2025

Across 11 payments — averaging $964.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$10K
  • Abbott$500
  • Abiomed$217
  • ZOLL Circulation Inc$123

What the payments were for

  • Consulting fees$14,7604%
  • Speaking & faculty fees$304,67580%
  • Grants$1000%
  • Travel & lodging$51,24313%
  • Food & beverage$9,5583%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$380,374 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$104,968
Medicare patients
357
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan42$56,259
EliquisApixaban55$47,972
FarxigaDapagliflozin Propanediol31$32,349
BrilintaTicagrelor35$24,282
XareltoRivaroxaban18$19,206
Ranolazine ErRanolazine18$1,809
Metoprolol Succinate89$941
Atorvastatin Calcium78$887
ClopidogrelClopidogrel Bisulfate75$845
Carvedilol72$630
Rosuvastatin Calcium35$542
Nitroglycerin30$407
Ezetimibe14$391
Metoprolol Tartrate45$370
Isosorbide Mononitrate ErIsosorbide Mononitrate27$351

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →